Breast Reconstruction in Metastatic Breast Cancer: Report of an Institutional Experience and Review of Literature

2017 ◽  
Vol 15 (1) ◽  
Author(s):  
Begoña Díaz de la Noval ◽  
Laura Frías Aldeguer ◽  
Shirin Zarbakhsh Etemandi ◽  
César Casado Sánchez ◽  
José Ignacio Sánchez-Méndez ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Breast Reconstruction ◽  
Metastatic Breast ◽  
Review Of Literature ◽  
Institutional Experience

The economic burden of metastatic breast cancer: A systematic review of literature from developed countries

2011 ◽  
Author(s):  
Talia S. Foster ◽  
Jeffrey D. Miller ◽  
Mark E. Boye ◽  
Marissa B. Blieden ◽  
Risha Gidwani ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Metastatic Breast Cancer ◽  
Economic Burden ◽  
Metastatic Breast ◽  
Developed Countries ◽  
Review Of Literature

Fatal hepatitis B reactivation due to everolimus in metastatic breast cancer: case report and review of literature

2013 ◽  
Vol 141 (2) ◽  
pp. 167-172 ◽  
Author(s):  
Eleonora Teplinsky ◽  
Derrick Cheung ◽  
Ilan Weisberg ◽  
Ramon E. A. Jacobs ◽  
Martin Wolff ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Case Report ◽  
Hepatitis B ◽  
Metastatic Breast ◽  
Breast Cancer Case ◽  
Cancer Case ◽  
Review Of Literature ◽  
Hepatitis B Reactivation

Efficacy and safety of combined trastuzumab and paclitaxel therapy as a second-line treatment in women with metastatic Breast Cancer: A single institutional experience

Breast Cancer ◽  
2006 ◽  
Vol 13 (4) ◽  
pp. 329-333 ◽  
Author(s):  
Keiko Furukawa ◽  
Yoshinori Ito ◽  
Shunji Takahashi ◽  
Masataka Sawaki ◽  
Nobuyuki Mizunuma ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Metastatic Breast ◽  
Line Treatment ◽  
Second Line ◽  
Efficacy And Safety ◽  
Institutional Experience

Use of alpelisib in the treatment of hormone receptor positive metastatic breast cancer: An institutional experience.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e15216-e15216
Author(s):  
Tsering G. Lama Tamang ◽  
Daniel Kyung ◽  
Lauren Eisenbud ◽  
Tianyi Tang ◽  
Ritesh Parajuli ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Pik3ca Mutation ◽  
Metastatic Breast ◽  
Pi3k Pathway ◽  
Real World Data ◽  
Tumor Registry ◽  
Hormone Receptor Positive ◽  
Heavily Pretreated ◽  
Institutional Experience

e15216 Background: Mutations in PI3K pathway is a known mechanism of resistance to endocrine therapy in breast cancer. Alpelisib is an alpha-specific PI3K inhibitor. Alpelisib with Fulvestrant is approved for treatment (Tx) of PIK3CA mutated HR+ metastatic breast cancer (MBC) that progress on hormonal therapy. Despite its approval by the FDA, real world data on the use of Alpelisib for the management of MBC is lacking. This abstract reviews the safety and efficacy of Alpelisib in the management of patients with MBC. Methods: A retrospective review of the tumor registry database at a single institution was conducted to identify patients with HR+ MBC. Detailed clinical and pathologic data of PIK3CA mutated patients treated with Alpelisib were obtained. Genomic profiling was done with Foundation One. Results: Table highlights the characteristics of the four patients. All were treated with Alpelisib and Fulvestrant after PIK3CA mutation was demonstrated. 3 patients were heavily pretreated with systemic Tx including CDK 4/6 inhibitors. All patients responded to Alpelisib and Fulvestrant despite treatment history. Mucositis, rash, hyperglycemia and pancytopenia were the observed adverse events (A/E). All A/E were adequately managed except in one patient that required discontinuation of Tx. None has clinically progressed. Conclusions: Our data suggests that Alpelisib and Fulvestrant is tolerated and improves outcomes in patients with HR+ MBC. Alpelisib and Fulvestrant could be an effective therapy in patients who have also progressed on systemic chemotherapy including CDK 4/6 inhibitors. Although our sample size is small, we hope that our experience could guide clinicians in the management of patients with HR+ MBC who harbor the PIK3CA mutation and are being treated with Alpelisib. [Table: see text]

Breast reconstruction in the patient with stable, metastatic breast cancer

2019 ◽  
Vol 26 (2) ◽  
pp. 335-336
Author(s):  
Shailesh Agarwal ◽  
David W. Chang
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Breast Reconstruction ◽  
Metastatic Breast

scholarly journals A role for hepatic surgery in patients with liver metastatic breast cancer: review of literature

2015 ◽  
Vol 2 (2) ◽  
pp. 159-170 ◽  
Author(s):  
Nicolae Bacalbaşa ◽  
Sorin Tiberiu Alexandrescu ◽  
Irinel Popescu
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Metastatic Breast ◽  
Review Of Literature ◽  
Hepatic Surgery ◽  
Cancer Review
Sign in / Sign up

Export Citation Format

Share Document